In this issue:
Tisagenlecleucel and axicabtagene ciloleucel CAR-T cells in large B cell lymphoma
Tumour debulking with ibrutinib before initiation of venetoclax
Phase 3 trial of gilteritinib plus azacitidine vs azacytidine
Ibrutinib improves survival compared with chemotherapy
Prognostic impact of NPM1 and FLT3 mutations in patients with AML
Low-dose dasatinib vs standarddose dasatinib as frontline therapy for CML
High baseline total lesion glycolysis predicts early POD
Patient trajectories after diagnosis of DLBCL
Second-line axicabtagene ciloleucel in R/R DLBCL
Ponatinib after the failure of second-generation TKI
Please login below to download this issue (PDF)